Candel Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CADL Nasdaq 2836 www.candeltx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Candel Therapeutics, Inc.

Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston - Jul 29th, 2026 6:05 am
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jul 8th, 2026 2:05 pm
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jul 1st, 2026 2:05 pm
CADL Stock Heads For Biggest Monthly Gains Since December 2024 – Retail Says ‘Our SLS Days Are Coming’ - Jun 30th, 2026 10:27 am
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors - Jun 30th, 2026 6:05 am
Candel Therapeutics Designates Mark Sims as CCO - Jun 25th, 2026 1:53 pm
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer - Jun 25th, 2026 6:05 am
CADL Stock Heads For Best Week In A Month – Here’s Why Retail Is Bullish - Jun 5th, 2026 4:23 am
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer - Jun 2nd, 2026 6:05 am
Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data - May 20th, 2026 9:13 am
Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade - May 19th, 2026 7:55 am
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting - May 15th, 2026 2:05 pm
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - May 14th, 2026 6:05 am
Candel Therapeutics to Present at Upcoming Investor Conferences - May 13th, 2026 6:05 am
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting - May 4th, 2026 6:05 am
Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch - Apr 29th, 2026 6:36 am
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer - Apr 29th, 2026 6:05 am
Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409 - Mar 17th, 2026 8:35 am
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors - Mar 17th, 2026 6:05 am
Candel Therapeutics strengthens balance sheet as lead cancer therapy advances - Mar 12th, 2026 7:33 am